Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239939 | 0.83 | HCRTR1 (0.39) | HCRTR1HCRTR2KCNH2PDFNPY5R | |
| SCHEMBL10241209 | 0.82 | HCRTR2 (0.43) | HCRTR1HCRTR2KCNH2NPY5R | |
| SCHEMBL9950023 | 0.79 | HCRTR2 (0.61) | HCRTR1HCRTR2KCNH2CYP2C8CYP2C19 | |
| SCHEMBL10239945 | 0.79 | HCRTR1 (0.47) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2619172 | 0.78 | HCRTR1 (0.53) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2618520 | 0.78 | HCRTR1 (0.64) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10266359 | 0.78 | HCRTR1 (0.53) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2619082 | 0.76 | HCRTR1 (0.64) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10241616 | 0.73 | HCRTR1 (0.40) | HCRTR1HCRTR2KCNH2PDFCHRM3 | |
| SCHEMBL10241215 | 0.72 | HCRTR1 (0.38) | HCRTR1HCRTR2KCNH2PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR1 2/4885HCRTR2 1/4885KCNH2 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.